Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Int J Surg Oncol. 2012;2012:613980. doi: 10.1155/2012/613980. Epub 2012 Aug 5.

The role of secondary surgery in recurrent ovarian cancer.

Author information

  • 1Fondazione IRCCS Istituto Nazionale Tumori, Via Venezian 1, 20133 Milan, Italy.


Despite optimal treatment (complete cytoreduction and adjuvant chemotherapy), 5-year survival for advanced ovarian cancer is approximately 30% and most patients succumb to their disease. Cytoreductive surgery is accepted as a major treatment of primary ovarian cancer but its role in recurrent disease is controversial and remains a field of discussion mainly owing to missing data from prospective randomized trials. A critical review of literature evidence on secondary surgery in recurrent ovarian cancer will be described.

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Hindawi Publishing Corporation Icon for PubMed Central
    Loading ...
    Write to the Help Desk